Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?

Pramanik, Raja; Tyagi, Asha; Chopra, Anita; Kumar, Akash; Vishnubhatla, Sreenivas; Bakhshi, Sameer

doi:10.1016/j.clml.2018.03.013

Cited by 23 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We, however, did not find differences in EFS and OS between the cytogenetic risk groups. The t(8;21) translocation, which is purported to be associated with superior outcomes, also did not lead to a better EFS and OS in the current series, a finding that has also been noted previously in AML patients from our institution 53 . Possibly, baseline cytogenetics do not have impact on second remission 34 .…”

Section: Discussionsupporting

confidence: 82%

“…The t(8;21) translocation, which is purported to be associated with superior outcomes, also did not lead to a better EFS and OS in the current series, a finding that has also been noted previously in AML patients from our institution. 53 Possibly, baseline cytogenetics do not have impact on second remission. 34 Another possible explanation is evolution of cytogenetic abnormalities in the AML clone, which has been reported to occur in more than half of AML patients between initial diagnosis and relapse.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India

Arora

Pushpam

Tiwari

et al. 2020

Pediatric Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India

Arora

Pushpam

Tiwari

et al. 2020

Pediatric Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most common clinical manifestations of intracranial myeloid sarcoma are headache, accompanied by numbness of limbs, blurred vision, epilepsy, etc. Common intracranial myeloid sarcoma gene mutation is t (8; 21), 10 which is the same as our case. Some others are t (15; 17) as in literature.…”

Section: Discussion and Literature Reviewsupporting

confidence: 76%

<p>Urgent Chemotherapy Successfully Rescues a Near Death Patient of Acute Intracranial Hypertension Caused by Intracranial Myeloid Sarcoma</p>

Zhou

Zhang

Feng

et al. 2020

OTT

View full text Add to dashboard Cite

Intracranial myeloid sarcoma is a very rare disease with poor prognosis. We report a case of a 28-year-old male patient who was admitted with intense headache, vision disturbance and severe vomiting in June 2017. He had a history of neurosurgical tumor resection operation in April 2017, and the pathological diagnosis was intracranial myeloid sarcoma. Bone marrow aspirate and biopsy had been conducted in May 2017, which demonstrated 5.5% blasts expressing CD13, CD33, CD34, CD117 and MPO, and the cytogenetic analysis demonstrated t(8;21)(q22;q22), and molecular studies showed a positive RUNX1-RUNX1T1 rearrangement. The diagnosis of acute myeloid leukemia (AML) with t (8; 21) (q22; q22)/RUNX1-RUNX1T1 was made, however, the patient refused to receive any systemic chemotherapy. Emergency cranial CT demonstrated a circular hyperdense mass (54mm×37mm), which was surrounded by hypodense peritumoral edema in the left cerebellar hemisphere, and the density of the lesions was uniform and the margin was clear. Idarubicin (12mg/m 2 •d×3 days) combined with high-dose cytarabine (2g/m 2 q12h×3 days) was initiated for emergency chemotherapy. All of the above symptoms disappeared at the end of chemotherapy. On the first day after chemotherapy, the cranial CT indicated that the cranial lesion was markedly reduced (20mm×15mm), and on the sixth day after chemotherapy, the lesion was completely disappeared. Currently, there are no clear guidelines for the treatment of intracranial myeloid sarcoma, and our treatment approaches could provide a reference for this disease with such emergency situation.

show abstract

“…The aetiology difference between granulocytic tumour and malign tumour is highly full of uncertainty; doubtful due to fault in GS/MS diagnosis. 7 In clinical histology, myeloid sarcoma is allied with AML/CML (acute/ chronic myeloid leukemia), sometimes refers as primary leukemia. 8 Moreover, another misdiagnosis happens in the cases of cancer of the lymphatic system i.e.…”

Section: Present Scenario: Diagnostic Paradigmsmentioning

confidence: 99%

Diagnostic dilemma and challenges of granulocytic sarcoma: a review

2021

HTIJ

View full text Add to dashboard Cite

The maleficent tumour granulocytic sarcoma is an unusual cancer indite of progressive myeloid precursor cells. It is a Chloroma basically present at an extramedullary location spread through immature granulocytic cells. It can affect any part of the body but the primary site is soft tissues, outside bone marrow, lymph nodes. The root cause may be many factors i.e. genetic, environmental, carcinogens etc. This proliferative type of cancer is sometimes misdiagnosis in contradictory to other acute/chronic tumours. For a histopathologist, it is a challenge for an accurate diagnosis. The tissue biopsy is the known diagnostic technique used since days in cancer diagnosis. To address this review, our main focus is to investigate, analyse the diagnostic limitations or research gaps in granulocytic sarcoma recognition at the clinical level and what can be the possibilities that have developed recently in tumour detection at an early stage. Next, we will try to develop a hypothesis from pinpoint methods used in it as molecular diagnosis, immune-histochemical biomarkers, flow cytometry (FACS) for confirmation of sarcoma so that specificity and sensitivity can be well examined. The prognosis/diagnosis in myeloid tumour detection depends on key factor innovation and medical devices and that should be filled in research and so a gold standard diagnostic kit should be developed.

show abstract

Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?

Cited by 23 publications

References 24 publications

Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India

Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India

<p>Urgent Chemotherapy Successfully Rescues a Near Death Patient of Acute Intracranial Hypertension Caused by Intracranial Myeloid Sarcoma</p>

Diagnostic dilemma and challenges of granulocytic sarcoma: a review

Contact Info

Product

Resources

About